March 5, 2026 — Leads & Copy — Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) has released its financial and operating results for the fourth quarter and year ended Dec. 31, 2025.
The company, a branded cannabis products leader and operator of Sunnyside dispensaries, reported all financial information in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated. The information is available on the company’s investor website.
Fiscal Year 2025 Highlights:
Revenue: $656 million.
Operating Cash Flow: $73 million.
Free Cash Flow: $38 million.
Gross Profit: $325 million.
Adjusted Gross Profit: $329 million.
Adjusted Gross Margin: 50.2%.
SG&A: $218 million.
Adjusted SG&A: Reduced by 5.7% year-over-year to $200 million, or 30.4%.
Net Loss: $140 million, including one-time, non-cash charges of $105 million related to the company’s impairment of intangibles and goodwill associated with the write-down of the New York reporting unit and fair value adjustments to the California reporting unit related to the sale of Sonoma’s Finest.
Adjusted EBITDA: $157 million.
Adjusted EBITDA Margin: 24.0%.
The company retained the No. 1 share position in multiple billion-dollar markets for the full year, according to Hoodie Analytics.
Fourth Quarter 2025 Highlights:
Revenue: $162 million.
Operating Cash Flow: $27 million.
Gross Profit: $83 million.
Adjusted Gross Profit: $84 million.
Adjusted Gross Margin: 52.2%.
SG&A: $57 million, or 35.3% of revenue.
Net Loss: $89 million, including one-time, non-cash charges of $93 million related to the write-down of the New York reporting unit.
Adjusted EBITDA: $40 million.
Adjusted EBITDA Margin: 25.0%.
The company retained the No. 1 share position in multiple billion-dollar markets, according to Hoodie Analytics.
Management Commentary:
“In Q4, we strengthened our financial foundation while expanding margins and generating meaningful cashflow,” the company stated. “We delivered $162 million in revenue, $40 million in Adjusted EBITDA, and $27 million in operating cashflow, with sequential improvement across multiple profitability metrics. Our focused strategy continues to enhance our competitive position.”
“The cannabis industry is consolidating in real time, and Cresco Labs is operating from a position of strength – we continue to show that we win where we operate. We are intentionally building a productive cash-generating platform, balancing organic expansion with selective, accretive acquisitions while maintaining a strong balance sheet. With leading brand share, differentiated retail execution, and embedded operating leverage, Cresco Labs is positioned to capitalize on industry consolidation and federal reform to create long-term value for shareholders.”
As of Dec. 31, 2025, current assets were $259 million, including cash, cash equivalents, and restricted cash of $91 million. An additional $3 million of restricted cash was classified as a non-current asset. The company had senior secured term loan debt, net of discount and issuance costs, of $311 million and a mortgage loan, net of discount and issuance costs, of $19 million.
Total shares on a fully converted basis to Subordinate Voting Shares were 491,585,556 as of Dec. 31, 2025.
The company hosted a conference call and webcast to discuss its financial results on Thursday, March 5, 2026, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). Archived access to the webcast will be available for one year on Cresco Labs’ investor website.
The financial information reported contains certain preliminary financial results for the three months and year ended Dec. 31, 2025. These financial statements have been prepared in accordance with U.S. GAAP. These preliminary results are provided prior to completion of all internal reviews and external audit procedures and are therefore subject to adjustment until the filing of the company’s audited consolidated financial statements, which the company expects to file on SEDAR+ and EDGAR on or about March 5, 2026. The audit of the consolidated financial statements for the year ended Dec. 31, 2025, is currently in process. All financial information is qualified in its entirety with reference to such financial statements.
Cresco Labs references certain non-GAAP financial measures, which may not be comparable to similar measures presented by other issuers.
Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi, on a national level. The company also operates highly productive dispensaries nationally under the Sunnyside brand.
Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible.
Source: Cresco Labs
